25 September 2018

Director/PDMR Dealing

The Company today announces that on 25 September 2018 David Evans, Chairman of the Company, has purchased 650,000 ordinary shares in the Company ("Ordinary Shares") at 3.75 pence per Ordinary Share.

Following these purchases, David Evans' total beneficial holding in the Company has increased to 43,187,411 Ordinary Shares representing 13.31 per cent. of the issued ordinary share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name David Evans
2 Reason for the notification
a) Position/status Chairman
b) Initial notification / Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name COLLAGEN SOLUTIONS PLC
b) LEI 213800IFY1CVGRGETL95
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary shares of 1p each

ISIN: GB00B94T6Y14
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
3.75p per share 650,000
d) Aggregated information
- Aggregated volume
- Price

N/A - single transaction
e) Date of the transaction 25 September 2018
f) Place of the transaction London Stock Exchange, XLON

 

Enquiries:

Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO
Via Walbrook
Cenkos Securities plc (Nominated Adviser and Broker)
Steve Cox (Corporate Finance)
Stephen Keys
Tel: 0207 397 8900
Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Helen Cresswell Mob: 07841 917 679

 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com